Abstract: Consumable products and methods for improving health, strength, and lifespan are disclosed. The products comprise non-refined complex carbohydrates (10 to 50% of total calories), and healthy fats (20 to 40%). The consumable products can also comprise proteins (30 to 60%). L-methionine may also be included. Consumable products are provided in various forms, including bars, shakes, powders, and frozen items. The methods involve substituting one or more meals with a consumable product for predetermined periods, offering nutritional benefits without calorie restriction, improving biomarkers, and reducing frailty.

Abstract: A method for treating depression in a human subject, which comprises administering for a first time period a fasting mimicking diet (FMD) component providing less than 50% of the normal calorie intake of the subject with both protein restriction and sugar restriction; and administering for a second time period a re-feeding diet component that provides 60-100% of the normal calorie intake of the subject; the fasting mimicking diet component and the re-feeding diet component are administered for multiple cycles, and the subject undergoes a psychotherapeutic treatment for the whole duration of the multiple cycles.

Abstract: A compound having antiestrogenic activity is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting mimicking diet for a period of 24-190 hours while the patient is being treated with the compound having antiestrogenic activity, which can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor downregulator (SERD) or an aromatase inhibitor (AI).

Abstract: A fasting mimicking diet package providing breakfast, lunch, and dinner meal portions for consumption during a one-day or single day fast. The one-day fasting mimicking diet package includes breakfast, lunch, and dinner meal portions for the one-day fast. The FMD package includes a breakfast meal portion having a first nut-containing nutrition bar composition, a micronutritional vegetable powder composition including vitamin and mineral supplements, an algal oil composition, a lunch meal portion that incorporates a first soup composition and a kale cracker composition, and a dinner meal portion having a second soup composition, one of either the kale cracker composition or an olive containing composition, and a second nut containing nutrition bar composition.

Abstract: A method for treating depression in a human subject, which comprises administering for a first time period a fasting mimicking diet (FMD) component providing less than 50% of the normal calorie intake of the subject with both protein restriction and sugar restriction; and administering for a second time period a re-feeding diet component that provides 60-100% of the normal calorie intake of the subject; the fasting mimicking diet component and the re-feeding diet component are administered for multiple cycles, and the subject undergoes a psychotherapeutic treatment for the whole duration of the multiple cycles.

Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitor to the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.

Abstract: A diet composition for use in the prevention and/or the treatment of endometrial hyperplasia in a human subject is provided. It has a) a fasting mimicking diet component to be administered for a first period of time and providing less than 50% of the normal caloric intake of the subject with both protein restriction and sugar restriction; and b) a re-feeding diet component to be administered for a second time period, which provides 60-100% of the normal caloric intake of the subject, wherein the fasting mimicking diet component and the re-feeding diet component are administered over multiple cycles.

Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitor to the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.

Abstract: A compound having antiestrogenic activity is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting mimicking diet for a period of 24-190 hours while the patient is being treated with the compound having antiestrogenic activity, which can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor downregulator (SERD) or an aromatase inhibitor (AI).

Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitorto the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.

Abstract: A tyrosine kinase inhibitor (TKI) for use in a method for the treatment of cancer in a patient, wherein the method comprises subjecting the patient to reduced caloric intake, i.e a daily caloric intake reduced by 10-100%, including starvation, for a period of 24-190 hours and administering the tyrosine kinase inhibitorto the patient during such period; the tyrosine kinase inhibitor is preferably selected among Lapatinib, Crizotinib, Gefitinib, Erlotinib, Afatinib and Regorafenib.